September 24, 2013 Read More →

Ultra-Rapid-Acting Inhaled Insulin Trial Funded By JDRF

JDRF, Sansum Diabetes Research Institute, and the College of Engineering at University of California, Santa Barbara (UCSB) are pleased to announce the first successful clinical research trial using the artificial pancreas in conjunction with ultra-rapid-acting inhaled insulin.
This represents a groundbreaking potential advancement in the treatment of type 1 diabetes (T1D). It establishes that the disease can be managed through a unified automated process that delivers precise amounts of insulin around the clock, based on real-time glucose measurements without the need for patient intervention, and is further enhanced and fine-tuned by the swift delivery of ultra-rapid-acting inhaled insulin during mealtimes. The artificial pancreas and inhaled insulin system work together to replicate the normal, healthy function of the human pancreas. Sansum Diabetes is the only site testing ultra-rapid-acting inhaled insulin in combination with the artificial pancreas. Read more …